Credit rating
Company information
About Troya Therapeutics ApS
Troya Therapeutics ApS (CVR number: 44032589) is a company from AARHUS. The company recorded a gross profit of -420.8 kDKK in 2023. The operating profit was -420.8 kDKK, while net earnings were -359.2 kDKK. The profitability of the company measured by Return on Assets (ROA) was -28.9 %, which can be considered poor and Return on Equity (ROE) was -31.7 %, which can be considered poor. The equity ratio, a key indicator for solidity, stood at -22 %. This indicates that the company's debt surpasses the value of its total assets, posing significant financial risk. Troya Therapeutics ApS's liquidity measured by quick ratio was 64.2 which is at a very high level. Thus, the company demonstrates exceptional financial stability, possessing a significant surplus of liquid assets over its short-term liabilities.
Financial information
See financialsGross profit (kDKK)
EBIT (kDKK)
Profitability
Solidity
Key figures (kDKK)
See financials2023 | |
---|---|
Volume | |
Net sales | |
Gross profit | - 420.77 |
EBIT | - 420.77 |
Net earnings | - 359.22 |
Shareholders equity total | - 319.22 |
Balance sheet total (assets) | 1 132.77 |
Net debt | 445.72 |
Profitability | |
EBIT-% | |
ROA | -28.9 % |
ROE | -31.7 % |
ROI | -29.2 % |
Economic value added (EVA) | - 329.26 |
Solvency | |
Equity ratio | -22.0 % |
Gearing | -451.1 % |
Relative net indebtedness % | |
Liquidity | |
Quick ratio | 64.2 |
Current ratio | 64.2 |
Cash and cash equivalents | 994.22 |
Capital use efficiency | |
Trade debtors turnover (days) | |
Net working capital % | |
Credit risk | |
Credit rating | B |
Variable visualization
Roles
Companies in the same industry
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.